ACLP-Logo

Advancing Integrated Psychiatric Care
for the Medically Ill

Member Portal

Our website is undergoing maintenance.

HIV Psychiatry Bibliography

HIV Psychiatry Bibliography

APM Research & Evidence-Based Practice Committees
Essential Scientific Publications for Psychosomatic Medicine

View the HIV Psychiatry Bibliography as PDF

Purpose

Over the past decades, HIV Psychiatry has emerged as a small subspecialty within APM. While not all APM psychiatrists will routinely care for patients infected with HIV/AIDS, most can play some role in the HIV epidemic (e.g., in screening efforts). The Academy’s Research and Evidence-based Practice Committees have coordinated a compilation of articles to identify essential scientific publications for members who are interested in learning more about critical issues in the care of patients infected with HIV/AIDS.

The purpose of the committee’s review was to create a list of important publications in three categories, based on specific review criteria related to scientific quality and relevance. You will see three categories of articles:

Tier 1: Randomized controlled trials, meta-analyses, or high-impact review articles
Tier 2: Comparison studies, non-randomized research of significance, highly relevant reviews
Tier 3: Other articles of interest related to HIV Psychiatry not meeting inclusion criteria for Tier 1 or Tier 2

Of note, this list is not a comprehensive list of all articles related to HIV Psychiatry but represents an attempt to identify a clinically useful selection of high-quality articles in this topic area. The most recent articles from 2012 and 2013 are in boldface type and supplied with a PubMed link. No articles older than 2000 were included.

Method

A MEDLINE review of literature was conducted to identify articles in the scientific literature related to HIV Psychiatry. Search terms included HIV, psychiatry, treatment, randomized-controlled trial, depression, psychosis, dementia, HIV-associated neurocognitive impairment, adherence, mania, anxiety, substance use, and epidemiology. In addition, articles and book chapters were reviewed to identify articles that appeared to be useful. Two APM expert reviewers (Oliver Freudenreich and Maria Ferrara) independently categorized the articles according to specific rating criteria (tiers 1, 2, and 3) and to specific categories of content (i.e., epidemiology, HIV-associated neurocognitive disorder (HAND), suicide, treatment (pharmacological and non-pharmacological), adherence, and other). Through an iterative process, consensus with regards to tier placement was achieved. Two other content matter experts (Mary Ann Cohen and Steven Safren) reviewed the bibliography list and made recommendations for additional articles to be included. Finally, the Research and Evidence-based Practice Committees reviewed the final list and approved it.

Back to top of pageA. Epidemiology

Tier 1

  1. McDonell MG, Srebnik D, Angelo F, McPherson S, Lowe JM, Sugar A, et al: Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness. Am J Psychiatry 2013; 170(1):94-101.
  2. Berkman A, Pilowsky DJ, Zybert PA, Herman DB, Conover S, Lemelle S, et al: HIV prevention with severely mentally ill men: a randomised controlled trial. AIDS Care 2007; 19(5):579-88.
  3. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al: Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58(8):721-8.

Tier 2

  1. Machtinger EL, Wilson TC, Haberer JE, Weiss DS: Psychological trauma and PTSD in HIV-positive women: a meta-analysis. AIDS Behav 2012; 16(8):2091-100.
  2. Meade CS: Sexual risk behavior among persons dually diagnosed with severe mental illness and substance use disorder. J Subst Abuse Treat 2006; 30(2):147-57.
  3. Nakimuli-Mpungu E, Musisi S, Mpungu SK, Katabira E: Primary mania versus HIV-related secondary mania in Uganda. Am J Psychiatry 2006; 163(8):1349-54; quiz 480.
  4. Carey MP, Carey KB, Maisto SA, Schroder KE, Vanable PA, Gordon CM: HIV risk behavior among psychiatric outpatients: association with psychiatric disorder, substance use disorder, and gender. J Nerv Ment Dis 2004; 192(4):289-96.
  5. Burnam MA, Bing EG, Morton SC, Sherbourne C, Fleishman JA, London AS, et al: Use of mental health and substance abuse treatment services among adults with HIV in the United States. Arch Gen Psychiatry 2001; 58(8):729-36.
  6. Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, Butterfield MI, et al: Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 2001; 91(1):31-7.

Tier 3

  1. Cohen, MA: How psychiatrists can prevent HIV transmission and provide compassionate care for persons with HIV and AIDS. Curr Psychiatry 2013 (in press).
  2. Mitchell AJ, Lord O, Malone D: Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis. Br J Psychiatry 2012; 201(6):435-43.
  3. Prince JD, Walkup J, Akincigil A, Amin S, Crystal S: Serious mental illness and risk of new HIV/AIDS diagnoses: an analysis of Medicaid beneficiaries in eight states. Psychiatr Serv 2012; 63(10):1032-8.
  4. Wyatt GE, Williams JK, Gupta A, Malebranche D: Are cultural values and beliefs included in U.S. based HIV interventions? Prev Med 2012; 55(5):362-70.
  5. Wu ES, Rothbard A, Blank MB: Using psychiatric symptomatology to assess risk for HIV infection in individuals with severe mental illness. Community Ment Health J 2011; 47(6):672-8.
  6. Sikkema KJ, Watt MH, Drabkin AS, Meade CS, Hansen NB, Pence BW: Mental health treatment to reduce HIV transmission risk behavior: a positive prevention model. AIDS Behav 2010; 14(2):252-62.
  7. Gaynes BN, Pence BW, Eron JJ, Jr., Miller WC: Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med 2008; 70(4):505-11.
  8. Meade CS, Graff FS, Griffin ML, Weiss RD: HIV risk behavior among patients with co-occurring bipolar and substance use disorders: associations with mania and drug abuse. Drug Alcohol Depend 2008; 92(1-3):296-300.
  9. Leserman J, Pence BW, Whetten K, Mugavero MJ, Thielman NM, Swartz MS, et al: Relation of lifetime trauma and depressive symptoms to mortality in HIV. Am J Psychiatry 2007; 164(11):1707-13.
  10. Marks G, Crepaz N, Senterfitt JW, Janssen RS: Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005; 39(4):446-53.
  11. Mills TC, Paul J, Stall R, Pollack L, Canchola J, Chang YJ, et al: Distress and depression in men who have sex with men: the Urban Men's Health Study. Am J Psychiatry 2004; 161(2):278-85.
  12. Walkup JT, Sambamoorthi U, Crystal S: Use of newer antiretroviral treatments among HIV-infected medicaid beneficiaries with serious mental illness. J Clin Psychiatry 2004; 65(9):1180-9.
  13. Rosenberg SD, Swanson JW, Wolford GL, Osher FC, Swartz MS, Essock SM, et al: The five-site health and risk study of blood-borne infections among persons with severe mental illness. Psychiatr Serv 2003; 54(6):827-35.
  14. Stein MD, Solomon DA, Herman DS, Anderson BJ, Miller I: Depression severity and drug injection HIV risk behaviors. Am J Psychiatry 2003; 160(9):1659-62.
  15. Vitiello B, Burnam MA, Bing EG, Beckman R, Shapiro MF: Use of psychotropic medications among HIV-infected patients in the United States. Am J Psychiatry 2003; 160(3):547-54.
  16. Morrison MF, Petitto JM, Ten Have T, Gettes DR, Chiappini MS, Weber AL, et al: Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry 2002; 159(5):789-96.

Back to top of pageB. HIV-Associated Neurocognitive Disorder (HAND)

Tier 1

  1. The Mind Exchange Working Group: Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 2013; 56(7):1004-17.
  2. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al: HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17(1):3-16.
  3. Heaton RK, Clifford DB, Franklin DR, Jr., Woods SP, Ake C, Vaida F, et al: HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75(23):2087-96.
  4. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al: Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69(18):1789-99.

Tier 2

  1. Crum-Cianflone NF, Moore DJ, Letendre S, Poehlman RM, Eberly L, Weintrob A, et al: Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology 2013; 80(4):371-379.
  2. Blackstone K, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, et al: Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol 2012; 26(6):894-908.
  3. Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, et al: CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. Aids 2011; 25(14):1747-51.
  4. Letendre S: Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 2011; 19(4):137-42.
  5. Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P: HIV-1 infection and cognitive impairment in the cART era: a review. Aids 2011; 25(5):561-75.
  6. Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, et al: Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis 2011; 204(5):753-60.
  7. Applebaum AJ, Otto MW, Richardson MA, Safren SA: Contributors to neuropsychological impairment in HIV-infected and HIV-uninfected opiate-dependent patients. J Clin Exp Neuropsychol 2010; 32(6):579-89.
  8. Letendre SL, Ellis RJ, Ances BM, McCutchan JA: Neurologic complications of HIV disease and their treatment. Top HIV Med 2010; 18(2):45-55.
  9. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, et al: Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. Aids 2010; 24(9):1243-50.
  10. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al: Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65(1):65-70.
  11. Cysique LA, Brew BJ, Halman M, Catalan J, Sacktor N, Price RW, et al: Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr 2005; 39(4):426-9.
  12. Cysique LA, Maruff P, Brew BJ: Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 2004; 10(6):350-7.
  13. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ: Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. Aids 2003; 17(10):1539-45.

Tier 3

  1. Kumar AM, Ownby RL, Waldrop-Valverde D, Fernandez B, Kumar M: Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. J Neurovirol 2011; 17(1):26-40.
  2. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, et al: Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009; 73(5):342-8.
  3. Ances BM, Ellis RJ: Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 2007; 27(1):86-92.
  4. Green JE, Saveanu RV, Bornstein RA. The effect of previous alcohol abuse on cognitive function in HIV infection. Am J Psychiatry 2004; 161(2):249-54.
  5. Jernigan TL, Gamst AC, Archibald SL, Fennema-Notestine C, Mindt MR, Marcotte TD, et al: Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 2005; 162(8):1461-72.

Back to top of pageC. Suicide

Tier 1

None

Tier 2

  1. Keiser O, Spoerri A, Brinkhof MW, Hasse B, Gayet-Ageron A, Tissot F, et al: Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008. Am J Psychiatry 2010; 167(2):143-50.

Tier 3

  1. Catalan J, Harding R, Sibley E, Clucas C, Croome N, Sherr L: HIV infection and mental health: suicidal behaviour--systematic review. Psychol Health Med 2011; 16(5):588-611.

Back to top of pageD. Treatment — Pharmacological Interventions

Tier 1

Epidemiology

  1. Lee S, Rothbard AB, Noll E, Blank MB: Use of HIV and psychotropic medications among persons with serious mental illness and HIV/AIDS. Adm Policy Ment Health 2011; 38(5):335-44.

Depression and fatigue

  1. Rabkin JG, McElhiney MC, Rabkin R: Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial. Psychosomatics 2011; 52(4):328-36.
  2. Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ: Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. J Clin Psychiatry 2010; 71(6):707-15.
  3. Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ, Ferrando SJ: Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry 2006; 163(1):59-66.
  4. Rabkin JG, Wagner GJ, McElhiney MC, Rabkin R, Lin SH: Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J Clin Psychopharmacol 2004; 24(4):379-85.
  5. Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J: A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001; 161(3):411-20.
  6. Rabkin JG, Wagner GJ, Rabkin R: A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000; 57(2):141-7; discussion 55-6.

Painful HIV neuropathy

  1. Simpson DM, Schifitto G, Clifford DB, Murphy TK, Durso-De Cruz E, Glue P, et al: Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 2010; 74(5):413-20.
  2. Simpson DM, McArthur JC, Olney R, Clifford D, So Y, Ross D, et al: Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003; 60(9):1508-14.

Tier 2

  1. Hahn K, Arendt G, Braun JS, von Giesen HJ, Husstedt IW, Maschke M, et al: A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004; 251(10):1260-6.
  2. Wagner GJ, Rabkin R: Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000; 61(6):436-40.

Tier 3

  1. Hill L, Lee KC: Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics. Ann Pharmacother 2013; 47(1):75-89.
  2. Gallego L, Barreiro P, Lopez-Ibor JJ: Psychopharmacological treatments in HIV patients under antiretroviral therapy. AIDS Rev 2012; 14(2):101-11.
  3. Watkins CC, Pieper AA, Treisman GJ: Safety considerations in drug treatment of depression in HIV-positive patients: an updated review. Drug Saf 2011; 34(8):623-39.
  4. Ferrando SJ, Freyberg Z: Treatment of depression in HIV positive individuals: a critical review. Int Rev Psychiatry 2008; 20(1):61-71.
  5. Rabkin JG: HIV and depression: 2008 review and update. Curr HIV/AIDS Rep 2008; 5(4):163-71.
  6. Repetto MJ, Petitto JM: Psychopharmacology in HIV-infected patients. Psychosom Med 2008; 70(5):585-92.
  7. Singh D, Goodkin K: Psychopharmacologic treatment response of HIV-infected patients to antipsychotic medications.
    J Clin Psychiatry 2007; 68(4):631-2.
  8. Olatunji BO, Mimiaga MJ, O'Cleirigh C, Safren SA: Review of treatment studies of depression in HIV. Top HIV Med 2006; 14(3):112-24.
  9. Himelhoch S, Medoff DR: Efficacy of antidepressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDS 2005; 19(12):813-22.

Drug-interactions

  1. Wynn GH, Cozza KL, Zapor MJ, Wortmann GW, Armstrong SC: Med-psych drug-drug interactions update. Antiretrovirals, part III: antiretrovirals and drugs of abuse. Psychosomatics 2005; 46(1):79-87.
  2. Zapor MJ, Cozza KL, Wynn GH, Wortmann GW, Armstrong SC: Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). Psychosomatics 2004; 45(6):524-35.
  3. Wynn GH, Zapor MJ, Smith BH, Wortmann G, Oesterheld JR, Armstrong SC, et al: Antiretrovirals, part 1: overview, history, and focus on protease inhibitors. Psychosomatics 2004; 45(3):262-70.

Back to top of pageE. Treatment — Non-Pharmacological Interventions

Tier 1

  1. Safren SA, O'Cleirigh CM, Skeer M, Elsesser SA, Mayer KH: Project enhance: a randomized controlled trial of an individualized HIV prevention intervention for HIV-infected men who have sex with men conducted in a primary care setting. Health Psychol 2013; 32(2):171-9.
  2. Safren SA, O'Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH: Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol 2012; 80(3):404-15.
  3. Duncan LG, Moskowitz JT, Neilands TB, Dilworth SE, Hecht FM, Johnson MO: Mindfulness-based stress reduction for HIV treatment side effects: a randomized, wait-list controlled trial. J Pain Symptom Manage 2012; 43(2):161-71.
  4. Kalichman SC, Cherry C, Kalichman MO, Amaral CM, White D, Pope H, et al: Integrated behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission. Am J Public Health 2011; 101(3):531-8.
  5. Sherr L, Clucas C, Harding R, Sibley E, Catalan J: HIV and depression--a systematic review of interventions. Psychol Health Med 2011; 16(5):493-527.
  6. Safren SA, O'Cleirigh C, Tan JY, Raminani SR, Reilly LC, Otto MW, et al: A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol 2009; 28(1):1-10.
  7. The Healthy Living Project: Effects of a behavioral intervention to reduce risk of transmission among people living with HIV: the healthy living project randomized controlled study. J Acquir Immune Defic Syndr 2007; 44(2):213-21.
  8. Himelhoch S, Medoff DR, Oyeniyi G: Efficacy of group psychotherapy to reduce depressive symptoms among HIV-infected individuals: a systematic review and meta-analysis. AIDS Patient Care STDS 2007; 21(10):732-9.
  9. Chesney MA, Chambers DB, Taylor JM, Johnson LM, Folkman S: Coping effectiveness training for men living with HIV: results from a randomized clinical trial testing a group-based intervention. Psychosom Med 2003; 65(6):1038-46.

Tier 2

  1. Antoni MH, Cruess S, Cruess DG, Kumar M, Lutgendorf S, Ironson G, et a: Cognitive-behavioral stress management reduces distress and 24-hour urinary free cortisol output among symptomatic HIV-infected gay men. Ann Behav Med 2000; 22(1):29-37.
  2. Cruess DG, Antoni MH, Schneiderman N, Ironson G, McCabe P, Fernandez JB, et al: Cognitive-behavioral stress management increases free testosterone and decreases psychological distress in HIV-seropositive men. Health Psychol 2000; 19(1):12-20.

Tier 3

  1. Olatunji BO, Mimiaga MJ, O'Cleirigh C, Safren SA: Review of treatment studies of depression in HIV. Top HIV Med 2006; 14(3):112-24.

Back to top of pageF. Adherence

Tier 1

  1. Tsai AC, Karasic DH, Hammer GP, Charlebois ED, Ragland K, Moss AR, et al: Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial. Am J Public Health 2013; 103(2):308-15.
  2. Gonzalez JS, Batchelder AW, Psaros C, Safren SA: Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr 2011; 58(2):181-7.
  3. Malta M, Strathdee SA, Magnanini MM, Bastos FI: Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 2008; 103(8):1242-57.

Tier 2

  1. Badiee J, Riggs PK, Rooney AS, Vaida F, Grant I, Atkinson JH, et al: Approaches to identifying appropriate medication adherence assessments for HIV infected individuals with comorbid bipolar disorder. AIDS Patient Care STDS 2012; 26(7):388-394.
  2. Mayston R, Kinyanda E, Chishinga N, Prince M, Patel V: Mental disorder and the outcome of HIV/AIDS in low-income and middle-income countries: a systematic review. Aids 2012; 26 Suppl 2:S117-35.
  3. Milloy MJ, Kerr T, Bangsberg DR, Buxton J, Parashar S, Guillemi S, et al: Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting. AIDS Patient Care STDS 2012; 26(1):60-7.
  4. Tsai AC, Weiser SD, Petersen ML, Ragland K, Kushel MB, Bangsberg DR: A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV. Arch Gen Psychiatry 2010; 67(12):1282-90.

Tier 3

  1. Blackstone K, Woods SP, Weber E, Grant I, Moore, DJ, HNRP Group: Memory-based strategies for antiretroviral medication management: an evaluation of clinical predictors, adherence behavior awareness, and effectiveness. AIDS Behav 2013; 17(1):74-85.
  2. Moore DJ, Posada C, Parikh M, Arce M, Vaida F, Riggs PK, et al: HIV-infected individuals with co-occurring bipolar disorder evidence poor antiretroviral and psychiatric medication adherence. AIDS Behiav 2012; 16(8):2257-2266.

Back to top of pageG. Other

Tier 1

Efavirenz

  1. Dabaghzadeh F, Ghaeli P, Khalili H, Alimadadi A, Jafari S, Akhondzadeh S, et al: Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial. AIDS Patient Care STDS 2013; 27(3):146-54.
  2. Read TR, Carey D, Mallon P, Mijch A, Goodall R, Hudson F, et al: Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. Aids 2009; 23(16):2222-3.
  3. Gutierrez-Valencia A, Viciana P, Palacios R, Ruiz-Valderas R, Lozano F, Terron A, et al: Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med 2009; 151(3):149-56.

Tier 2

  1. Kenedi CA, Goforth HW: A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav 2011; 15(8):1803-18.

Screening

  1. Sanger C, Hayward J, Patel G, Phekoo K, Poots AJ, Howe C, et al: Acceptability and necessity of HIV and other blood-borne virus testing in a psychiatric setting. Br J Psychiatry 2013; 202(4):307-8.
  2. Senn TE, Carey MP: HIV testing among individuals with a severe mental illness: review, suggestions for research, and clinical implications. Psychol Med 2009; 39(3):355-63.
  3. Meade CS, Sikkema KJ: Voluntary HIV testing among adults with severe mental illness: frequency and associated factors. AIDS Behav 2005; 9(4):465-73.
  4. Walkup J, Satriano J, Barry D, Sadler P, Cournos F: HIV testing policy and serious mental illness. Am J Public Health 2002; 92(12):1931-40.

Smoking

  1. Lifson AR, Lando HA: Smoking and HIV: prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep 2012; 9(3):223-30.

Tier 3

Education

  1. Cohen MA, Forstein M: A biopsychosocial approach to HIV/AIDS education for psychiatry residents. Acad Psychiatry 2012; 36(6):479-86.

Valproic acid

  1. Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, et al: Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med 2012; 13(5):291-6.

Back to top of pageADDENDUM

Books about HIV Psychiatry

  • Handbook of AIDS Psychiatry by Mary Ann Cohen, Harold Goforth, Joseph Lux, et al. Oxford University Press, 2010.
  • Comprehensive Textbook of AIDS Psychiatry by Mary Ann Cohen and Jack M. Gorman (editors). Oxford University Press, 2008.
  • Psychiatric Aspects of HIV/AIDS by Francisco Fernandez and Pedro Ruiz (editors). Lippincott Williams & Wilkins, 2006.
  • The Psychiatry of AIDS: A Guide to Diagnosis and Treatment by Glen J. Treisman and Andrew F. Angelino. The Johns Hopkins University Press, 2004.

HIV Clinical Guidelines

  • New York State Department of Health AIDS Institute in collaboration with Johns Hopkins University Division of Infectious Diseases:
    http://www.hivguidelines.org/

Back to top of pageAUTHORS

  • Oliver Freudenreich, MD, FAPM
  • Maria Ferrara, MD

For the APM Research & Evidence-Based Practice Committee

ACKNOWLEDGMENTS

APM Research and Evidencce-Based Practice Committee:

  • Michael Sharpe, MD, FAPM
  • Robert Boland, MD, FAPM
  • Oliver Freudenreich, MD, FAPM
  • Jeff Huffman, MD, FAPM

We would like to thank Mary Ann Cohen, MD, FAPM and Steven Safren, PhD for independently reviewing the tiered list and making recommendations for additional papers.